Praxis Precision Medicines to Release Phase 2 EMBOLD Study Data on Relutrigine in SCN2A and SCN8A Encephalopathies on September 3, 2024
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those involving an imbalance in neuronal excitation and inhibition. On September 2, 2024, the company announced that it would be revealing the topline results from its Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on the morning of September 3, 2024, before the market opens.
The announcement of the trial results will be followed by a conference call and webcast presentation scheduled for 8:00 a.m. ET on September 3. After the live presentation, a replay will be made available on Praxis’ website under the investor section.
Praxis Precision Medicines is leveraging genetic insights to discover and develop therapies for CNS disorders. The company uses its proprietary small molecule platform, Cerebrum™, along with the antisense oligonucleotide (ASO) platform, Solidus™, to target shared biological mechanisms in the brain. By focusing on these targets, Praxis aims to address both rare and more widespread neurological disorders.
The company’s diverse CNS portfolio includes multiple programs targeting movement disorders and epilepsy, with four clinical-stage product candidates currently in development. Praxis' approach involves translating genetic data into therapeutic strategies that could potentially improve treatment outcomes for patients suffering from various neurological conditions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
